title: [Stem cell transplantation in myelofibrosis].
abstract: Allogeneic hematopoietic stem cell transplantation (ASCT) offers the only potentially curative therapy for myelofibrosis, a malignant myeloproliferative disease. The transplant-related mortality is still high, 10-48%, but use of reduced-intensity conditioning is less toxic and allows transplantation to be performed up to 65-70 years of age. Fabourable treatment response will be attained at least in a third of patients, in another third the disease will progress, and nearly one third will succumb due to transplant complications. Thirteen patients with myelofibrosis underwent ASCT at our institution between 1999 and 2009. The outcome of the patients treated with reduced-intensity conditioning corresponds well with those reported in the literature.
authors.affiliation: Turun yliopisto.
authors.forename: Aura
authors.initials: A
authors.lastname: Toivari
authors.forename: Maija
authors.initials: M
authors.lastname: Itälä-Remes
authors.forename: Marjut
authors.initials: M
authors.lastname: Kauppila
authors.forename: Mervi
authors.initials: M
authors.lastname: Putkonen
authors.forename: Urpu
authors.initials: U
authors.lastname: Salmenniemi
authors.forename: Kari
authors.initials: K
authors.lastname: Remes
mesh_terms: D000367:Age Factors; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D055728:Primary Myelofibrosis / Q000401:mortality / Q000628:therapy*; D033581:Stem Cell Transplantation / Q000401:mortality; D019172:Transplantation Conditioning / Q000379:methods; D016896:Treatment Outcome